Ketolides

Definition

Ketolides are a subclass of macrolide antibiotics structurally derived from erythromycin A, developed to overcome macrolide-resistant bacteria, particularly in respiratory tract infections. Their structure includes a 3-keto group instead of the cladinose sugar found in macrolides, giving them unique pharmacological properties.

---

Pharmacological Background

Ketolides exhibit broad-spectrum activity against Gram-positive respiratory pathogens, including strains resistant to traditional macrolides, due to their improved binding affinity to bacterial ribosomal RNA. While they share the macrolide core (14-membered lactone ring), ketolides are considered semisynthetic antibiotics with modifications that enhance ribosome binding, reduce inducible resistance, and provide a longer half-life.

---

Mechanism of Action

• Ketolides bind to the 50S subunit of the bacterial ribosome, specifically targeting domains II and V of 23S rRNA.

• This dual binding distinguishes them from macrolides (which bind only domain V) and is critical in overcoming erm gene-mediated resistance.

• The result is inhibition of bacterial protein synthesis, leading to bacteriostatic or bactericidal activity depending on concentration and organism.

---

Antibacterial Spectrum

Effective Against:

• Streptococcus pneumoniae (including macrolide-resistant strains)

• Haemophilus influenzae

• Moraxella catarrhalis

• Mycoplasma pneumoniae

• Chlamydophila pneumoniae

• Legionella pneumophila

• Streptococcus pyogenes (limited clinical use due to risk of resistance)

Not Effective Against:

• Most Gram-negative enteric bacilli

• Pseudomonas aeruginosa

• Anaerobes (limited activity)

• Methicillin-resistant Staphylococcus aureus (MRSA)

---

Approved Ketolides

1. Telithromycin

• Brand Name: Ketek

• Approval: First and only FDA-approved ketolide (2004)

• Formulation: Oral tablets (300 mg and 400 mg)

• Typical Dose: 800 mg once daily for 5–7 days

Clinical Uses (approved indications):

• Community-acquired bacterial pneumonia (CABP) caused by susceptible strains

• Formerly used for acute bacterial sinusitis and exacerbations of chronic bronchitis, but these indications were withdrawn due to safety concerns

---

Pharmacokinetics

• Absorption: ~57% oral bioavailability

• Distribution: Extensive tissue penetration (especially pulmonary tissue and macrophages)

• Half-life: ~10 hours

• Protein binding: ~60–70%

• Metabolism: Hepatic (CYP3A4)

• Elimination: Primarily via biliary excretion, some renal excretion

---

Resistance Mechanisms

Ketolides were specifically designed to overcome macrolide resistance, particularly:

• MLS_B resistance (erm genes): Alters the ribosomal target site → ketolides retain activity due to dual binding domains.

• Efflux pumps (mef genes): Reduced effectiveness compared to macrolides but not entirely immune.

• Mutation in ribosomal RNA: Resistance can still occur if mutations affect both binding domains.

Note: Despite structural advantages, resistance is increasing due to widespread antibiotic exposure.

---

Adverse Effects

While ketolides were developed for better safety and efficacy, serious adverse reactions have limited their widespread use:

Common:

• Nausea

• Diarrhea

• Dizziness

• Headache

• Visual disturbances

Serious:

• Hepatotoxicity: Black box warning for telithromycin; cases of acute liver failure have occurred

• QT interval prolongation: Risk of torsades de pointes

• Exacerbation of myasthenia gravis: Contraindicated in these patients

• Loss of consciousness (rare): Due to vagal stimulation or visual disturbances

---

Contraindications and Precautions

• Myasthenia gravis: Absolute contraindication due to risk of fatal respiratory failure

• Hepatic impairment: Monitor liver enzymes; avoid in severe liver disease

• Concurrent QT-prolonging medications: Avoid co-administration

• CYP3A4 inhibitors or substrates: Caution due to metabolism interference

• Hypersensitivity to macrolides or ketolides

---

Drug Interactions

• Telithromycin inhibits CYP3A4: Increases serum levels of drugs like simvastatin, midazolam, carbamazepine

• Avoid with ergot alkaloids: Risk of ergotism

• Warfarin: INR may be elevated

• Digoxin: Increased serum levels possible

---

Clinical Uses and Guidelines

Although telithromycin was initially positioned as a first-line agent for respiratory infections, its use today is limited due to safety concerns. The FDA has restricted its indications to CABP only, and many clinicians avoid its use altogether in favor of newer macrolides or fluoroquinolones.

---

Limitations and Safety Controversies

• Telithromycin was withdrawn or restricted in several countries due to its risk of hepatotoxicity, including acute liver failure and death.

• Post-marketing surveillance revealed serious adverse outcomes not seen during clinical trials.

• Case reports of visual disturbances and syncope prompted further scrutiny.

As a result:

• Telithromycin is rarely prescribed today

• No newer ketolides have been FDA-approved since

• Research into safer ketolide analogs continues, particularly those with less hepatotoxicity and CYP3A4 interaction

---

Second-Generation / Investigational Ketolides

Several next-generation ketolides are under preclinical or clinical development with improved safety profiles:

Solithromycin

• Brand name: (Investigational – Cempra Pharmaceuticals)

• Indication: CABP, pediatric infections, and sexually transmitted infections

• Form: Oral and IV

• Improved binding affinity and safety profile compared to telithromycin

• FDA status: Not approved due to unresolved safety concerns, particularly hepatotoxicity

• Still under review in some jurisdictions

Cethromycin

• Developed for respiratory infections and as prophylaxis against inhalational anthrax

• Showed promise but never reached final FDA approval

---

Storage and Stability

• Telithromycin tablets: Store at room temperature (20°C to 25°C)

• Protect from moisture and light

• Discard expired tablets as per pharmaceutical disposal guidelines

---

Clinical Role in 2025

Currently, ketolides are not widely recommended in clinical practice due to:

• Narrow therapeutic index

• Risk of serious side effects

• Effective alternatives (e.g., azithromycin, doxycycline, fluoroquinolones)

However, they remain an option for macrolide-resistant pneumococcal infections in specific, supervised cases.

---

Ketolides vs. Macrolides: Key Differences

Feature	Ketolides	Macrolides
Structure	3-keto group replaces cladinose	Contains cladinose sugar
Binding site	Dual site on 23S rRNA (domains II and V)	Single site (domain V)
Activity	Retains effect in MLS_B resistance	Loses activity in MLS_B
CYP3A4 inhibition	Strong (e.g., telithromycin)	Moderate (e.g., erythromycin)
Risk of hepatotoxicity	Higher	Lower
Current use	Limited (telithromycin only)	Broad (azithromycin, clarithromycin)

Summary of Key Properties of Telithromycin

• Class: Ketolide antibiotic

• Brand: Ketek

• Route: Oral

• Dose: 800 mg once daily

• Indication: Community-acquired bacterial pneumonia (CABP)

• Half-life: 10 hours

• Hepatic metabolism: Yes (CYP3A4)

• Main risk: Hepatotoxicity

• Status: FDA restricted; limited clinical use

---

Conclusion of Clinical Relevance

The emergence of macrolide-resistant respiratory pathogens initially gave ketolides a promising role in infectious disease management. However, due to serious adverse effects—particularly hepatotoxicity—clinical confidence in ketolides has waned. Currently, telithromycin remains the only approved ketolide, but its use is severely restricted, and newer ketolides are still undergoing safety evaluation.